Merck Announces FDA Acceptance of Biologics License Application for Immunotherapy Tablet
News Mar 28, 2013
In March, the company also submitted a BLA to the FDA for its investigational ragweed pollen (Ambrosia artemisiifolia) AIT.
The BLA for Merck’s grass pollen AIT is supported by Phase III trials that evaluated the safety and efficacy of the investigational product, including a long-term, multi-season trial.
“We are pleased to have achieved this important milestone in the development of our investigational grass pollen AIT, which, if approved, would represent a potential new option for allergy specialists to offer appropriate allergic rhinitis patients,” said Jeffrey A. Chodakewitz, M.D., senior vice president, Global Scientific Strategy, franchise head, Infectious Diseases and interim franchise head, Respiratory & Immunology, Merck Research Laboratories.
Merck's grass pollen (Phleum pratense) AIT is an investigational sublingual dissolvable tablet designed to help treat the underlying cause of allergic rhinitis by generating an immune response to help protect against targeted allergens. Merck has partnered with ALK-Abello to develop its grass pollen (Phleum pratense) AIT in North America.
Measuring Neutrophil Motility Could Lead to Accurate Sepsis DiagnosisNews
Mass. General researchers design device that rapidly diagnoses sepsis with more than 95 percent accuracy.READ MORE
Malaria Prevention: New Antibody Targets Unique Binding SiteNews
Scientists have discovered a human antibody that, when tested in mice, prevented malaria infection by binding a specific portion of a surface protein found in almost all strains of the malaria parasite worldwide.READ MORE
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
Comments | 0 ADD COMMENT
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018
World Congress on Plant Science and Molecular Biology
Sep 12 - Sep 13, 2018